These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23068961)

  • 21. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can GLP-1 preparations be used in children and adolescents with diabetes mellitus?
    Shehadeh N; Daich E; Zuckerman-Levin N
    Pediatr Endocrinol Rev; 2014 Mar; 11(3):324-7. PubMed ID: 24716398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
    Santilli F; Simeone PG; Guagnano MT; Leo M; Maccarone MT; Di Castelnuovo A; Sborgia C; Bonadonna RC; Angelucci E; Federico V; Cianfarani S; Manzoli L; Davì G; Tartaro A; Consoli A
    Diabetes Care; 2017 Nov; 40(11):1556-1564. PubMed ID: 28912305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
    Sugii H; Matsumura Y; Inoue A; Horigome H; Matsuzaki K; Shimizu A
    Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):233-41. PubMed ID: 20948161
    [No Abstract]   [Full Text] [Related]  

  • 25. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes.
    Iwao T; Sakai K; Sata M
    J Diabetes Complications; 2013; 27(1):87-91. PubMed ID: 22863615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
    Ellenbroek JH; Töns HA; Westerouen van Meeteren MJ; de Graaf N; Hanegraaf MA; Rabelink TJ; Carlotti F; de Koning EJ
    Diabetologia; 2013 Sep; 56(9):1980-6. PubMed ID: 23771206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liraglutide: a once-daily human glucagon-like peptide-1 analogue.
    Aimaretti G
    J Endocrinol Invest; 2009 Sep; 32(8):701-3. PubMed ID: 19942822
    [No Abstract]   [Full Text] [Related]  

  • 31. Fasting serum total bile acid levels are associated with insulin sensitivity, islet β-cell function and glucagon levels in response to glucose challenge in patients with type 2 diabetes.
    Wang XH; Xu F; Cheng M; Wang X; Zhang DM; Zhao LH; Cai HL; Huang HY; Chen T; Zhang XL; Wang XQ; Cheng XB; Su JB; Lu Y
    Endocr J; 2020 Nov; 67(11):1107-1117. PubMed ID: 32684527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation.
    Usui R; Sakuramachi Y; Seino Y; Murotani K; Kuwata H; Tatsuoka H; Hamamoto Y; Kurose T; Seino Y; Yabe D
    J Diabetes Investig; 2018 Jul; 9(4):822-830. PubMed ID: 29106046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incretins: a new treatment option for type 2 diabetes?
    Geelhoed-Duijvestijn PH
    Neth J Med; 2007 Feb; 65(2):60-4. PubMed ID: 17379930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma.
    Ruby RJ; Armato JP; Pyke C; Peters AL
    Diabetes Care; 2014 Aug; 37(8):e177-8. PubMed ID: 25061148
    [No Abstract]   [Full Text] [Related]  

  • 35. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.
    Hegedüs L; Moses AC; Zdravkovic M; Le Thi T; Daniels GH
    J Clin Endocrinol Metab; 2011 Mar; 96(3):853-60. PubMed ID: 21209033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY; Ryder RE; Cull ML; Walton C;
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.
    Varanasi A; Patel P; Makdissi A; Dhindsa S; Chaudhuri A; Dandona P
    Endocr Pract; 2012; 18(2):140-5. PubMed ID: 21856595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
    Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418
    [No Abstract]   [Full Text] [Related]  

  • 39. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved glycemic control enhances the incretin effect in patients with type 2 diabetes.
    An Z; Prigeon RL; D'Alessio DA
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4702-8. PubMed ID: 24092826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.